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1478Objectives: A significant evolution has occurred in surgical ablation for atrial fibrillation (AF) toward alternate
energy sources, lesion sets, and approaches, with the intent of simplifying the Cox maze III operation and
maintaining similar outcomes. Because no large comparative studies with long-term follow-up exist, we have
reviewed our experience.
Methods: From January 1993 to January 2011, 1540 patients underwent surgical ablation for AF. The operations
were performed in conjunction with repair of congenital heart disease in 351 (30%) and adult-acquired disease
in 1189 patients (70%). In the 1189 patients, preoperative AF was paroxysmal in 598 (50%) and persistent in
591 (50%). The energy sources included cut and sew in 521 (44%), cryothermy in 267 (22%), radiofrequency in
262 (22%), and a combination in 139 patients (12%). The lesion sets included biatrial in 810 (68%), isolated
pulmonary vein isolation in 269 (23%), and isolated left atrial in 110 (9%). AF ablation was performed during
isolated mitral valve surgery in 516 patients (43%).
Results: The median follow-up was 33 months (maximum, 20.3 years), and late rhythm follow-up was available
for 80%. The cut and sew Cox maze III procedure was superior at each follow-up interval (P¼ .01, P¼ .03, and
P<.001). On multivariate analysis, the cut and sew maze procedure was independently associated with less risk
of recurrent AF at a follow-up period of 1 to 5 years (hazard ratio, 0.4; 95% confidence interval, 0.24-0.69;
P< .001) and>5 years (hazard ratio, 0.23; 95% confidence interval, 0.12-0.42; P< .001) for all patients.
When performed during isolated mitral valve surgery, the cut and sew Cox maze III was also independently
associated with less risk of recurrent AF at>5 years (hazard ratio, 0.23; 95% confidence interval, 0.08-0.66;
P ¼ .007).
Conclusions: The cut and sew Cox maze III procedure appears to offer significantly greater freedom from AF
without antiarrhythmic medications compared with alternate energy sources and lesion sets. Although alternate
energy sources offer the advantage of quicker application and the possibility of minimally invasive applications,
the Cox maze III operation arguably remains the reference standard for the surgical treatment of AF and should
still be considered, especially for patients for whom AF ablation is of critical importance. (J Thorac Cardiovasc
Surg 2014;147:1478-87)Since its introduction, the cut and sew Cox maze III
procedure has served as the reference standard for the
surgical treatment of atrial fibrillation (AF).1-3 Rigorously
evaluating the outcomes after the Cox maze III procedure
was facilitated by the consistent nature of its lesion set
and the absolute guarantee of obtaining transmural
lesions. Since then, it has served as the foundation for thehe Division of Cardiovascular Surgery, Mayo Clinic and Foundation,
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The Journal of Thoracic and Cardiovascular Suradditional development and evolution of contemporary
techniques for the surgical ablation of AF.
In the current era, the Cox maze III procedure has largely
become a historical operation as various ablative energy
sources and alternate lesion sets have become available
and have been most commonly applied in practice.4
Subsequently, a rigorous evaluation of rhythm outcomes
has become extremely challenging and plagued by
heterogeneity. Thus, disagreement now exists regarding
the optimal approach, whether it is type of energy source
or which lesion set to be applied in what clinical setting.
In addition, the underlying issue of reliably creating
transmural lesions remains for every alternate ablative
technology. Although consensus statements now exist in
an effort to standardize the practice of surgical AF ablation
and outcomes reporting,5,6 a lack of uniformity continues to
exist in the published data, further complicating the
assessment of current approaches.gery c May 2014
Abbreviations and Acronyms
AAM ¼ antiarrhythmic medication
AF ¼ atrial fibrillation
BA ¼ biatrial
CI ¼ confidence interval
CSM ¼ cut and sew Cox maze III procedure
HR ¼ hazard ratio
HRS ¼ Heart Rhythm Society
LA ¼ left atrial
NYHA ¼ New York Heart Association
PVI ¼ pulmonary vein isolation
RF ¼ radiofrequency
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DBecause no large comparative series with long-term
follow-up data have been published, we report our
experience with the surgical treatment of AF for 2 decades.
The goals of the present study were to (1) describe our
surgical approach throughout the study period, (2) report
the rhythm outcomes for all surgical approaches, and
(3) identify the independent predictors associated with
recurrent AF during early (<1 year), midterm (1-5 years),
and late (>5 years) follow-up.
METHODS
The Mayo Foundation institutional review board approved the present
study, and all patients or their families provided written informed consent.
Patients
From March 5, 1993 to January 1, 2011, 1540 patients underwent
surgical ablation for AF. Surgery for AF was performed in conjunction
with repair of congenital heart disease in 351 patients (30%) and
adult-acquired disease in 1189 patients (70%). The latter cohort of patients
was the focus of the present review. The median age at surgery was 66 years
(range, 22-91) and 707 were men (59%). The type of preoperative AF was
paroxysmal in 598 patients (50%) and persistent in 591 (50%).
The preoperative clinical characteristics include hypertension in 700
patients (59%), hypercholesterolemia in 396 (33%), congestive heart
failure in 279 (23%), and diabetes in 127 (11%). Preoperatively, 116
patients (10%) were in New York Heart Association (NYHA) functional
class I, 373 (31%) were in class II, 621 (52%) were in class III, and 77
(7%) were in class IV. The patients were analyzed as an entire cohort
and separately according to the type of lesion set that was performed at
surgery. These included biatrial (BA) in 810 patients (68%), pulmonary
vein isolation (PVI) alone in 269 (23%), and complete left atrial (LA) in
110 (9%). Additional delineations of preoperative clinical characteristics
according to separate patient groups within the overall cohort are listed
in Table 1. Statistically significant differences were found among the study
groups in terms of age (P< .001), paroxysmal AF (P< .001), diabetes
(P ¼ .028), and hypertension (P<.001).
Definitions
We classified the type AF present according to the Heart Rhythm
Society (HRS)/European Heart Rhythm Association/European Cardiac
Arrhythmia Society Expert Consensus Statement, in collaboration with
the American College of Cardiology, Society of Thoracic Surgeons, and
American Heart Association.5,6 Paroxysmal AF was defined by recurrentThe Journal of Thoracic and Car(2) episodes of AF that were self-terminating. Persistent AF was defined
by a continuous episode of AF that was present for>7 days or<7 days but
required medical or electrical conversion. Longstanding persistent AF was
considered present when a patient had continuous AF for>1 year. We have
reported success as freedom from AF without antiarrhythmic medications
(AAMs), also in accordance with the consensus statement.
Surgical Ablation Descriptions
For the cut and sew Cox maze III procedure (CSM), the lesions were
performed as described by Cox and colleagues,1 using cardiopulmonary
bypass with normothermia or moderate hypothermia (28-32C). We
used 2 minor modifications to the original Cox maze procedure, as we
have reported previously.3 Cryoablation was performed using a variety of
probes, including Frigitronics (CooperVision, Inc, Lake Forest, Calif)
and CryoCath (Medtronic, Montreal, Quebec, Canada). Cryolesions were
created with the cryoprobe for 1 minute (maximum, 2.5) at 60C.
With bipolar radiofrequency (RF), the device gave feedback when the
lesion was transmural, and a minimum of 2 applications were applied.
Depending on the quality and thickness of the atrial tissue, multiple
applications were often used. Bipolar RF was performed using either the
AtriCure device (AtriCure, Inc, Cincinnati, Ohio) or the Cardioblate device
(Medtronic, Inc, Minneapolis, Minn). The lesion sets employed using these
alternate energy sources were (1) isolated PVI, achieved from either an
epicardial approach isolating each side separately or an endocardial
approach and including all veins within a box; (2) a LA lesion set, which
added a connecting lesion to the LA appendage and to the mitral valve
annulus from the PVI line, and included cryoablation at the mitral valve
annulus; and (3) a complete BA lesion set, which mimicked the Cox
maze III lesions, more recently termed the ‘‘Cox maze IV’’ procedure.7
Importantly, we have continued to use cryolesions at the mitral and
tricuspid valve annuli and to create the transseptal lesion, similar to our
approach in the standard Cox maze III procedure.
Postoperative Care
The potassium and magnesium levels were maintained in the high
normal range, and diuretics were used early after surgery, as needed, to
prevent fluid retention. If postoperative AF occurred, the patients were
treated with amiodarone and electrical cardioversion was used as needed;
amiodarone was then continued for 3 months. All patients were dismissed
with warfarin and advised to continue anticoagulation for a minimum of 3
months. The continuation or discontinuation of warfarin or AAMs was at
the discretion of the patient’s primary cardiologist or primary care
physician, depending on the clinical setting and cardiac rhythm.
Follow-up Data
The demographic and other patient-related data were obtained from the
Mayo Clinic medical records and our prospective clinical database.
Follow-up information was obtained from subsequent clinic visits, written
correspondence from local physicians, and mailed questionnaires to the
patients or families. The rhythm was evaluated using an electrocardiogram
(ECG) obtained 3 months after surgery; this served as the blanking
period.
Statistical Analysis
Continuous data are expressed as either the mean  standard deviation
or median and range. The data between 2 groups were compared using
Student’s paired t test, and the data among>2 groups were compared using
1-way analysis of variance. The risk factors were assessed using log-rank
analysis. The variables significant on univariate analysis were used during
stepwise selection to create the final multivariate model. Early operative
mortality was defined as death occurring within 30 days of surgery or at
any point during the index hospitalization. Analysis was performed on
the entire patient cohort and the separate patient cohorts according to thediovascular Surgery c Volume 147, Number 5 1479
TABLE 1. Preoperative clinical characteristics
Clinical
variable
CSM
(n ¼ 514)
PVI
(n ¼ 269)
LA
(n ¼ 110)
BA-A
(n ¼ 296)
P
value
Age 62 68 68 68 <.001
Paroxysmal AF 172 (33) 218 (81) 82 (75) 126 (43) <.001
Diabetes 9 (8) 36 (13) 11 (10) 40 (14) .028
Hypertension 267 (52) 185 (69) 65 (59) 182 (61) <.001
Data presented as n (%). CSM, Cut and sew Cox maze III procedure; PVI, pulmonary
vein isolation; LA, left atrial; BA-A, biatrial with alternative sources of energy;
AF, atrial fibrillation.
TABLE 2. Operative characteristics
Operative variable
CSM
(n ¼ 514)
PVI
(n ¼ 269)
LA
(n ¼ 110)
BA-A
(n ¼ 296)
P
value
MV surgery 308 (60) 105 (39) 96 (87) 204 (69) <.001
Crossclamp
time (min)
59  5 65  6 81  6 85  6 <.001
Bypass time (min) 103  7 90  8 109  7 119  7 <.001
LAA ligation 514 (100) 188 (70) 88 (80) 218 (74) <.001
Data presented as n (%) or mean  standard deviation. CSM, Cut and sew Cox maze
III procedure; PVI, pulmonary vein isolation; LA, left atrial; BA-A, biatrial with
alternative sources of energy; MV, mitral valve; LAA, left atrial ablation.
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set, and BA lesion set using alternate energy sources. The analysis of
outcomes was performed for patients for whom follow-up data were
available. The patients were censored and not included in the postoperative
analysis if follow-up data were unable to be obtained.
RESULTS
Operative Data
All patients underwent surgical ablation of AF. For the
entire cohort, the lesion sets performed included BA in
810 patients (68%), PVI alone in 269 (23%), and complete
LA in 110 (9%). For the 810 patients who received a BA
lesion set, the CSM was performed in 514 patients (63%)
and alternate energy sources were used to mimic the classic
Cox maze III lesions in 296 (37%). The energy sources
used for the creation of lesions included CSM in 521
patients (44%), cryothermy in 267 (22%), RF in 262
(22%), and a combination of energy sources in 139 (12%).
For the 269 patients who underwent isolated PVI, the
energy sources included CSM in 2 patients (1%), RF in
181 (67%), cryothermy in 67 (25%), and a combination
in 19 (7%). For the 110 patients who underwent an LA
lesion set, the energy sources included CSM in 5 patients
(5%), RF in 25 (23%), cryothermy in 55 (50%), and a
combination in 25 (22%). For the 296 patients who
underwent a BA lesion set using alternate technology,
the energy sources included RF in 56 patients (19%),
cryothermy in 144 (49%), and a combination in 95 (32%).
The cardiac operations performed during surgical
ablation of AF included mitral valve surgery in 713 patients
(60%), coronary artery bypass grafting in 257 (22%),
tricuspid valve surgery in 205 (17%), and aortic valve
surgery in 190 (16%). The LA appendage was amputated
or ligated in 1008 patients (84%). The median crossclamp
time was 59 minutes (range, 13-376), and the median
cardiopulmonary bypass time was 92 minutes (range,
11-579). Additional delineations of the operative data
stratified according to the lesion set performed are listed
in Table 2. Statistically significant differences were present
among the study groups in terms of mitral valve surgery
(P < .001), crossclamp time (P < .001), bypass time
(P<.001), and LA appendage ligation (P<.001).
The approaches to surgical AF ablation evolved
during the study period. The types of lesion sets performed1480 The Journal of Thoracic and Cardiovascular Suraccording to year are shown in Figure 1. An increase
occurred in the focal lesion sets (PVI and LA) through the
study period. The energy sources used according to year
are shown in Figure 2. An increase in the alternate energy
sources (RF, cryothermy, and combined) through the study
period. The use of the classic CSM procedure according to
year is shown in Figure 3. However, an increase in the use of
alternative lesion sets and energy sources was seen through
the study period.
Early Outcomes
Early nonfatal morbidity for the entire cohort included
re-exploration for bleeding in 58 patients (4.9%), new
permanent pacemaker placement in 44 (3.7%), renal failure
in 37 (3%; 23 required dialysis), superficial wound
infection in 13 (1.1%), and neurologic events in 13
(1.1%; 11 with stroke and 2 with transient ischemic attack).
Seventy-four early deaths (6.2%) occurred. The delineation
of the early postoperative outcomes stratified according to
lesion set performed is listed in Table 3.
Follow-up
For the entire cohort, the median follow-up period was
34 months (range, 3 month to 20.4 years), and rhythm
follow-up data were available for 891 of the 1115 early
survivors (80%) for a median of 38 months (range, 5
months to 18.5 years). The median length of rhythm
follow-up varied significantly among patients who
underwent differing surgical approaches to AF ablation:
CSM (57 months; range, 3 months to 18.5 years), PVI
(30 months; range 3 months to 8 years), LA (26 months;
range 3 months to 10.2 years), and BA with alternative
energy sources (26 months; range, 3 months to 9.5 years;
P<.001).
Rhythm Outcomes
Freedom from AF without AAMs at the last follow-up
point for the entire cohort was 72%; after CSM, isolated
PVI, LA, and BA with alternative energy sources was
80%, 63%, 78%, and 61%, respectively (P < .001).
Because significant disparities existed in the follow-up
duration, we analyzed the freedom from AF withoutgery c May 2014
FIGURE 1. Types of lesion sets performed according to year. An increase was seen in focal lesion sets (pulmonary vein isolation [PVI] and left atrial [LA])
throughout the study period.
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DAAMs at 3 different intervals:<1, 1 to 5, and>5 years. The
most recent ECG available during each interval was used
for rhythm analysis. The overall freedom from AF without
AAM rate at each follow-up interval according to the type
of ablative energy source is presented in Figure 4. CSM
was superior at <1, 1 to 5, and >5 years (P ¼ .01,
P ¼ .03, and P< .001, respectively). The rate of overallFIGURE 2. Energy sources used according to year. An increase was seen
and combined) through the study period.
The Journal of Thoracic and Carfreedom from AF without AAM at each follow-up interval
according to the type of lesion set is presented in Figure 5.
The BA and complete LA lesion sets were superior at>5
years after surgery (P ¼ .004). The Cox maze III procedure
was associated with significantly greater freedom from AF
without AAM compared with the BA lesion set performed
with alternate energy sources (80% vs 61%, P<.001).in alternate energy sources (radiofrequency [RF], cryothermy [Cryo],
diovascular Surgery c Volume 147, Number 5 1481
FIGURE 3. The use of the classic cut and sew Cox maze III (CSM) procedure according to year. An increase was seen in the use of alternative lesion sets
and energy sources throughout the study period.
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populations by performing a stepwise backward multi-
variate logistic regression analysis. For the entire cohort,
<1 year after surgical AF ablation age (per 5 years; hazard
ratio [HR], 1.44; 95% confidence interval [CI], 1.2-1.7;
P<.001) was independently associated with less freedom
from AF without AAMs. At 1 to 5 years after surgery,
preoperative paroxysmal AF (HR, 0.33; 95% CI, 0.2-0.5;
P < .001), the Cox maze III operation (HR, 0.4; 95%
CI, 0.2-0.7; P< .001), and isolated mitral valve surgery
(HR, 0.6; 95% CI, 0.4-0.96; P ¼ .03) were independently
associated with greater freedom from AF without AAMs.
Age (per 5 years; HR, 1.11; 95% CI, 1-1.2; P ¼ .048)
was independently associated with less freedom from AF
without AAMs. At follow-up>5 years, the Cox maze III
operation (HR, 0.23; 95% CI, 0.12-0.42; P < .001)
and preoperative paroxysmal AF (HR, 0.36; 95% CI,TABLE 3. Early nonfatal morbidity
Early outcome
CSM
(n ¼ 514)
PVI
(n ¼ 269)
LA
(n ¼ 110)
BA-A
(n ¼ 296)
P
value
Reoperation for
bleeding
33 (6) 8 (3) 1 (1) 16 (5) .04
Postoperative stroke 6 (1) 2 (1) 0 (0) 4 (1) <.66
Renal failure 10 (2) 9 (3) 3 (3) 15 (5) .13
Early PPM 12 (2) 7 (3) 3 (3) 22 (7) .003
Early death 12 (2) 28 (10) 12 (11) 22 (7) <.001
Data presented as n (%) or mean  standard deviation. CSM, Cut and sew Cox maze
III procedure; PVI, pulmonary vein isolation; LA, left atrial; BA-A, biatrial with
alternative sources of energy; PPM, permanent pacemaker.
1482 The Journal of Thoracic and Cardiovascular Sur0.2-0.66; P ¼ .001) were independently associated with
greater freedom from AF without AAMs, and preoperative
NYHA functional class III-IV (HR, 1.84; 95% CI,
1.04-3.27; P ¼ .036) was independently associated with
less freedom from AF without AAMs.Isolated Mitral Valve Surgery
Patients undergoing isolated mitral valve surgery and
concomitant surgical ablation of AF represented the largest
single patient cohort (n ¼ 516). Thus, to attempt to adjust
for confounders, we also analyzed this subgroup. The
energy sources used to create lesions included CSM in
266 patients (52%), RF in 73 (14%), cryothermy in 113
(22%), and a combination in 64 (12%). Paroxysmal AF
was present in 234 patients (45%). The lesion sets included
PVI in 68 patients (13%), LA in 79 (15%), and BA in 369
(72%). The classic Cox maze III procedure was performed
in 256 patients (50%). The overall freedom from AF
without AAMs was 71%. The rhythm outcome stratified
according to the interval of follow-up and type of ablative
energy performed is presented in Figure 6. CSM was
associated with significantly greater freedom from AF
without AAMs after 5 years postoperatively (P ¼ .03).
The overall freedom from AF without AAMs at each
follow-up interval according to the type of lesion set
demonstrated no difference at any follow-up point
(P ¼ .1, P ¼ .5, and P ¼ .8). However, patients undergoing
the Cox maze III procedure concurrent with isolated mitral
valve surgery resulted in significantly greater freedom fromgery c May 2014
FIGURE 4. Overall freedom from atrial fibrillation without antiarrhythmic medication (%) at each follow-up point according to type of ablative
energy source. Cut and sew was superior at each follow-up interval (P ¼ .01, P ¼ .03, and P<.001, respectively). Cryo, Cryothermy; RF, radiofrequency.
*Statistically significant difference.
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AF ablation within 1 year postoperatively (87% vs 70%,
P ¼ .04) and after 5 years postoperatively (75% vs 52%,
P ¼ .03).
Less than 1 year after surgical AF ablation, female
gender (HR, 4.9; 95% CI, 1.03-23.02; P ¼ .045) wasFIGURE 5. Overall freedom from atrial fibrillation without antiarrhythmic me
Biatrial and complete left atrial (LA) lesion sets were superior at>5 years posto
vein isolation.
The Journal of Thoracic and Carindependently associated with less freedom from AF
without AAMs. At 1 to 5 years of follow-up, preoperative
paroxysmal AF (HR, 0.25; 95% CI, 0.11-0.58;
P ¼ .0013) independently predicted greater freedom from
AF without AAMs and female gender (HR, 2.34; 95%
CI, 1.01-5.4; P ¼ .046), less freedom from AF withoutdication (%) at each follow-up interval according to the type of lesion set.
peratively (P ¼ .004). *Statistically significant difference. PVI, Pulmonary
diovascular Surgery c Volume 147, Number 5 1483
FIGURE 6. Freedom from atrial fibrillation without antiarrhythmic medication (%) at each follow-up interval according to type of ablative energy
performed for patients who underwent isolated mitral valve surgery. Cut and sew was associated with significantly greater freedom from atrial fibrillation
without antiarrhythmic medication after 5 years postoperatively (P ¼ .03). *Statistically significant difference.
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DAAMs. At >5 years of follow-up, the Cox maze III
operation (HR, 0.23; 95% CI, 0.08-0.66; P ¼ .007) and
preoperative paroxysmal AF (HR, 0.27; 95% CI,
0.1-0.71; P ¼ .009) independently predicted greater
freedom from AF without AAMs, and preoperative
NYHA functional class III-IV (HR, 2.86; 95% CI,
1.14-7.17; P ¼ .025) was independently associated with
less freedom from AF without AAMs.
DISCUSSION
We have demonstrated that freedom from AF without
AAMs will be significantly greater in patients undergoing
the Cox maze III procedure than in patients undergoing
surgical AF ablation with alternate energy sources and
lesion sets at all follow-up points. Furthermore, for all
patients, the Cox maze III procedure was independently
associated with greater freedom from AF without AAMs
>1 year postoperatively on multivariate analysis. Freedom
from AF without AAMs was significantly greater at late
follow-up for patients undergoing isolated mitral valve
surgery and the concomitant Cox maze III procedure.
The evolution of our practice has mirrored that of
the contemporary cardiac surgical community,8 with
significantly more patients undergoing surgical AF ablation
with alternate lesion sets (Figure 1) and alternate energy
sources (Figure 2) compared with the Cox maze III
procedure (Figure 3). In analyzing our large experience,
we encountered challenges similar to those of others, in
that the present series was heterogeneous, with multiple1484 The Journal of Thoracic and Cardiovascular Sursubgroups requiring analysis. We have previously
performed and reported a case-matched series evaluating
new technologies compared with the Cox maze III
procedure; however, we did not do this in the present
series.9 To account for the varying patient characteristics,
lesion sets, and energy sources, we used a multivariate
model to identify the independent predictive factors.
With so many permutations of patient subgroups (eg,
preoperative AF type, energy source, lesion set, type of
concomitant cardiac surgical procedure), the small numbers
in each subgroup detracted from a meaningful and robust
subgroup analysis. We did analyze our largest patient
subgroup, and, arguably, the most relevant in clinical
practice for surgical AF ablation. Our largest subgroup
was the patients who underwent mitral valve surgery and
concomitant surgical AF ablation. Even within this
subgroup, the indications, and procedures performed, for
mitral valve pathologic features were heterogeneous.
These challenges will continue in the analysis of surgical
AF ablation; however, an honest attempt to control for these
differences will continue to be of paramount importance.
For all patients, we observed that CSM as an energy
source was associated with greater freedom from AF
without AAMs at all follow-up points after surgery
compared with alternate energy sources (RF, cryothermy,
or a combination). In terms of the lesion sets, a complete
LA and BA lesion set were associated with greater success
at>5 years of postoperative follow-up. The Cox maze III
procedure was significantly more effective than the PVIgery c May 2014
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Dand LA lesion set during all follow-up points. However,
because this was not a fair comparison of similar
procedures, we more specifically examined the Cox maze
III procedure compared with the BA lesion set performed
with alternate energy sources (RF, cryothermy, or a
combination). The classic Cox maze III procedure resulted
in significantly greater freedom from AF without AAMs in
this setting. After accounting for the confounders, on
multivariate analysis, the Cox maze III procedure was
independently associated with greater success>1 year after
surgery. For patients undergoing isolated mitral valve
surgery and concomitant AF ablation, neither the lesion
set nor the energy source yielded a greater success rate of
AF ablation compared with one another on its own.
However, when a Cox maze III procedure was performed,
the success within 1 year and after 5 years postoperatively
was significantly greater.
New technologies and new approaches have been aimed
at simplifying lesion sets and shortening the time needed to
create atrial ablation lines7 compared with the technical
complexity associated with the Cox maze III procedure.
Consequently, the issue of ensuring completely transmural
lesions remains unresolved. Also, because only midterm
follow-up data are available, the long-term natural history
of these lesions remains undefined. Of the larger series
examining the Cox maze IV procedure (range, 94-250
patients), the maximum follow-up has ranged from
12 months to 3.6 years, with large variability.10-14
Furthermore, new technology and approaches have
facilitated the advent of minimally invasive surgical AF
ablation. Experience with this technology is even less
mature (687 patients in 14 series) and only early-term
results (follow-up range, 6-17months) have been published.
Only 10 of 16 studies have reported outcomes in adherence
with current consensus, with success rates ranging
from 57% to 88%.15 Although alternate technology and
approaches to surgical AF ablation have continued to evolve
and attempted to replicate the results from the Cox maze III
procedure, it is imperative that standardized evaluations are
undertaken to draw firm conclusions.
Although much focus on surgical AF ablation has been
on the energy sources, lesion sets, and approaches,
patient-related factors can influence greatly the outcomes,
and all these factors need to be considered together and
not in isolation. We observed the greatest success with
CSM as an energy source; however, no difference were
found between any single lesion set at<5 years postopera-
tively. However, when the energy source and lesion set were
combined in the analysis, the Cox maze III procedure
(cut and sew with the BA lesion set) proved the most
effective. Preoperative paroxysmal AF, older age, and
NYHA functional class III-IV were also independently
predictive of recurrent AF, not only for the entire cohort,
but also were most predictive<5 years after isolated mitralThe Journal of Thoracic and Carvalve surgery. It was only until>5 years postoperatively
that the Cox maze III procedure was independently
predictive of greater success. Analyzing the outcomes of
surgical AF ablation has become quite complex, and
many more factors need to be evaluated than just the lesion
set or energy source.
Study Limitations
The major limitation of the present series was the
heterogeneity of the patient population, a common
challenge in series examining the outcomes of surgical
ablation of AF. We attempted to account for confounders
by performing narrower subgroup analyses and performing
a multivariate analysis and entering all pertinent variables
for evaluation. In addition, we conformed to the current
consensus statement in terms of the definition of AF type
and lesion sets and reporting outcomes in an attempt
to lessen the heterogeneity. The present study was a
retrospective review and possessed all the inherent
limitations of this type of study design. All rhythm
outcomes were obtained from electrocardiographic reports.
When a 24-hour Holter monitor was available, which was
the minority of the time, we confirmed the rhythm observed
on the ECG. Although the best monitoring modality has yet
to be defined, electrocardiography has been shown to
overestimate success by>10% compared with long-term
monitoring.16,17 Follow-up data were not available for all
patients; thus, the outcomes we have reported might not
reflect the true outcomes.
Event monitoring was discussed in the HRS consensus
statement as the standard method to evaluate patients after
surgical ablation of AF. We acknowledge that our use of
electrocardiography was not in accordance with that
statement. Although we do use event monitoring in the
current era, for the evaluation of our patients after AF
ablation before 2007, the year the HRS statement was
published, we used electrocardiography, which was
acceptable. However, our report spans 2 decades; thus, if
a comparison will done with patients who have undergone
a procedure used most commonly before the HRS
statement in 2007, electrocardiography would still need to
be used. Although studies have indicated that this might
overestimate success, we decided to use this method
consistently and homogeneously for all patients, with the
hope that if an overestimation was present, it would be uni-
form across all patient populations. It would not make sense
to use electrocardiographic follow-up for the maze patients
who had undergone surgery 15 years earlier and than
compare that with the event monitoring for patients who
had had alternate energy sources used in the current era.
CONCLUSIONS
In our experience, the standard cut and sew Cox maze III
operation has been the most reliable and effective method todiovascular Surgery c Volume 147, Number 5 1485
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potential for ablation of AF. Furthermore, as observed in
the present series, the Cox maze III procedure offers
significantly greater freedom from AF compared with
alternate energy sources and lesion sets. Patient factors,
including risks and benefits, should always be considered
when planning AF ablation to optimize the lesion set and
energy source applied. Although wemight consider isolated
PVI to potentially be adequate for a patient with paroxysmal
AF, a more complete BA lesion set might be required for
patients with more long-standing AF and complex
valvular disease, in whom the pathogenesis of AF could
be completely different. It is not clear whether newer
procedures have definitively demonstrated equivalency to
the Cox maze III procedure with limited series and
follow-up data. Although these technologies and alternate
approaches can be appropriate in select patients, the Cox
maze III procedure remains the reference standard for the
surgical treatment of AF and should still be considered,
especially for patients for whom AF ablation is of critical
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Dr Ralph J. Damiano, Jr (St Louis, Mo). Dr Stulak, thank you
for providing me with the report and congratulations on a superb
presentation.
This is a very interesting study, and I think it illustrates one of
the problems with looking back at a long retrospective experience
from either a single or multiple centers. One of the greatest
problems with your data is that the groups were extremely
heterogeneous, just as you have alluded, and it is almost
impossible to account for all those variables when you examine
your data.
Perhaps the most single important variable is the surgeon
experience and technical proficiency with the different procedures.
My first question for you is whether you controlled for the surgeon
performing the ablation procedures? I know historically at least at
your institution, Dr Schaff has been a real proponent of the cut and
sew procedure. If he performed all the cut and sew operations and
other surgeons with varying levels of experience performed the
other ablation procedures, how did you take that into account?
Dr Stulak. That is a great point. We did not control for the
surgeon. Just as I stated in the last line, I do not know how
generalizable our data will be, because this was basically our
experience. Actually 4 surgeons throughout the study period
performed the CSM, with the 90-whatever percent performed by
Dr Schaff; thus, this was almost a comparison of what he
does during his mitral valve operations compared with 8 to
12 other surgeons during that same period using alternate energy
sources. So, you were exactly right, it would be difficult to control
for that.
But this is not the end game for us. This is just the beginning,
studying how we can better evaluate new technology and control
for confounders at the same time. I think I have learned a lot
and will continue to do so.
Dr Damiano. No, I think that is a really important point. You
really cannot underestimate that variable.
I will just share an anecdote from one of the large multicenter
trials in which we recruited a number of centers, all with very
experienced surgeons who all were trained to perform the Cox
maze IV procedure. The center-to-center variability in the success
rate, as adjudicated by an independent core laboratory, ranged
from 0% to 100%. You might say that this is either the greatest
procedure ever invented or the worst. But it really is related to
how it was performed. The take home message from your study
should not be that one should always perform a Cox maze III
procedure. Because it is interesting, even at your own institution,gery c May 2014
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Dif the CSM was that great, how come you did not perform it more
frequently?
Dr Stulak. No, absolutely. I think the message from our
report is, is that results are different. Also, although we have this
new technology, we should not become complacent and say,
‘‘Wow, we have this great technology.’’ We can compare it with
an operation we know has yielded wonderful results and for us
to continue to evolve and always improve that technology. We
are certainly not saying ‘‘let us go back in time,’’ necessarily
because of the reasons it was abandoned in the first place probably.
However, I think there still is a niche for it, and I think it does serve,
we have the most data for it; thus, I think it will serve as a
comparator group as we move toward new technologies and
approaches.
DrDamiano.Yes, I think that is an excellent point, that it serves
as a great reference standard.
My last question and comment on your data is that, although
admittedly the guidelines were not published until 2007,
when we present reports on the surgical ablation of AF it is
not adequate just to present electrocardiograph follow-up data.
We know that that really underestimates the rate. Do you have a
subset of patients that met the minimum criteria for follow-up,
which would be a 24-hour Holter or pacemaker interrogation,The Journal of Thoracic and Carand have you studied your results when you have adequate
follow-up data?
Dr Stulak. This is a great point. Unfortunately, we did not
have Holter monitoring data for the comparator group, and we
believe that using 2 different methods of rhythm evaluation
would not have been appropriate. We have begun to follow
patients with Holter monitoring during follow-up in the current
era. However, if you use the same monitoring method for all
patients, you would like to assume that it would overestimate the
success for all patients. Thus,wewanted to at least not compareHol-
ter versus old-time ECGs. So, you are right, although that was one
caveat that I throw myself on the sword for in the presentation, we
had to have similar comparator groups, at least for this analysis.
Dr Damiano. A final quick question. Many of the large studies
have shown for both catheter and surgical ablation that LA size is a
predictor of failure. I notice that did not come out in your
multivariate analysis. Is that because you did not have enough
data, particularly from the older part of your series, or was that
really not a predictor of failure?
Dr Stulak. No, in our earlier report we saw a 55-mm cutoff.
This did not come out. I would suggest that we did not have
adequate echocardiographic data beforehand, either, in patients
undergoing coronary artery bypass grafting.diovascular Surgery c Volume 147, Number 5 1487
